-
ProjectsCG-0255 (IV)TargetsP2Y12 AntagonistIndications
- Adjunct to percutaneous coronary intervention (PCI), and adjunct to endovascular mechanical recanalization for AIS
Early
discoveryPreclinical
studiesPhase
IPhase
ⅡPhase
ⅢNDACG-0255 (IV)? CG-0255 is the world’s first thioether hydrolysis-based prodrug and a next-generation of antiplatelet agent;
? High potential for accelerated approval in stroke prevention and treatment of acute coronary syndrome, myocardial infarction (MI), and peripheral arterial diseases. -
ProjectsCG-0255 (PO)TargetsP2Y12 AntagonistIndications
- Acute coronary syndrome, recent MI, recent stroke, or established peripheral arterial disease
Early
discoveryPreclinical
studiesPhase
IPhase
ⅡPhase
ⅢNDACG-0255 (PO)? CG-0255 is the world’s first thioether hydrolysis-based prodrug and a next-generation of antiplatelet agent;
? High potential for accelerated approval in stroke prevention and treatment of acute coronary syndrome, myocardial infarction (MI), and peripheral arterial diseases. -
ProjectsCG-0416TargetsTHR-βIndications
- MASLD/MASH
Early
discoveryPreclinical
studiesPhase
IPhase
ⅡPhase
ⅢNDACG-0416? CG-0416 is a first-in-class THR-β-targeted prodrug designed for MASH, achieving hepatic-specific activation to drive comprehensive reduction of hepatic fat, inflammation, and fibrosis.
? Its synergistic combination with GLP-1 RA enhances weight loss and lipid control while uniquely addressing muscle preservation risks associated with metabolic therapies.
-
ProjectsCG-0985TargetsRdRp InhibitorIndications
- Broad-spectrum antiviral drug for respiratory infections
Early
discoveryPreclinical
studiesPhase
IPhase
IIPhase
IIINDACG-0985CG-0985 is a small molecule direct antiviral drug with broad-spectrum antiviral activity. It is effective against a variety of common respiratory RNA viruses including the SARS2 virus, respiratory syncytial virus (RSV), metapneumovirus (hMPV), parainfluenza viruses, common coronaviruses, rhinoviruses, etc. It has good safety profile and could potentially meet the clinical needs of a wide range of population for the treatment as well as post-exposure prophylaxis of viral infections. CG-0985 is expected to cover the unmet medical needs for this tremendous market lacking effective treatment and prevention options. -
ProjectsCG-1999TargetsImmune modulatorIndications
- Functional cure for chronic
- hepatitis B
Early
discoveryPreclinical
studiesPhase
IPhase
IIPhase
IIINDACG-1999? CG-0199 is an innovative immunomodulator independently developed by CureGene;
? Based on the widely accepted comprehensive strategy of direct antiviral + viral gene expression inhibitor and comprehensive immunomodulation for functional cure of chronic hepatitis B, this product can effectively stimulate the specific immune mechanism of the organism, and become the core therapeutic component of drug combination to achieve the functional cure of chronic hepatitis B;